Orchestra BioMed Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing the entry into an underwriting agreement and the closing of an underwritten public offering of common stock that generated approximately $86.3 million in gross proceeds.

Key Highlights

  • Offering size: 15,000,000 shares of common stock were offered at a public offering price of $5.00 per share.
  • Overallotment exercised in full: The underwriters held an option to purchase up to 2,250,000 additional shares, which was exercised in full on November 6, 2026.
  • Gross proceeds: Approximately $86.3 million, before deducting underwriting discounts, commissions, and other offering expenses.
  • Underwriters: Piper Sandler & Co. and TD Securities (USA) LLC acted as representatives of the several underwriters.
  • Closing date: The offering closed on November 9, 2026.
  • Intended use of proceeds: The company stated it intends to fund its Atrioventricular Interval Modulation Therapy program, the BACKBEAT global pivotal trial, its Virtue SAB program, the Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial, research and clinical development, and working capital and general corporate purposes.

Orchestra BioMed's November 2026 Public Offering: Terms and Intended Use of Proceeds

According to the filing, Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) entered into the underwriting agreement on November 5, 2026, with Piper Sandler & Co. and TD Securities (USA) LLC as representatives of the underwriters. The offering comprised 15,000,000 shares of common stock, par value $0.0001 per share, priced at $5.00 per share. The company also granted the underwriters a 30-day option to purchase up to 2,250,000 additional shares, and that option was exercised in full on November 6, 2026, the filing disclosed.

The offering was made pursuant to the company's registration statement on Form S-3 (File No. 333-279430), which was previously filed with the SEC on May 15, 2024, and declared effective on May 24, 2024. A final prospectus supplement dated November 5, 2026, was filed with the SEC on November 6, 2026, according to the filing. Gross proceeds were reported as approximately $86.3 million before deducting underwriting discounts, commissions, and other offering expenses payable by the company.

The company disclosed that it intends to use net proceeds, together with its existing cash and cash equivalents, to advance its Atrioventricular Interval Modulation Therapy program and the BACKBEAT global pivotal trial, which involves patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker. Proceeds will also support the Virtue Sirolimus AngioInfusion Balloon program and the Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial, as well as research and clinical development of other current or additional product candidates, with the remainder for working capital and general corporate purposes. The filing notes that statements regarding use of proceeds are forward-looking and subject to risks and uncertainties identified in the company's cautionary language.

What Was Disclosed

Orchestra BioMed filed an 8-K reporting the November 5, 2026, underwriting agreement and the November 9, 2026, closing of a public offering of 15,000,000 shares plus 2,250,000 overallotment shares at $5.00 per share, generating approximately $86.3 million in gross proceeds.